Brain atrophy and cognitive deficits in Cushing’s disease

CHIRAG G. PATIL, M.D., SHIVANAND P. LAD, M.D., PH.D., LAURENCE KATZNELSON, M.D., AND EDWARD R. LAWS, JR., M.D.

Department of Neurosurgery, Stanford University School of Medicine, Stanford, California

Cushing’s disease results from sustained pathological hypercortisolism secondary to excessive adrenocorticotropic hormone secretion by tumors of the pituitary gland. Clinical features of Cushing’s disease such as abnormal fat distribution, wide violaceous striae, hirsutism, impaired glucose tolerance, and osteoporosis are often discussed and investigated. The experienced clinician, however, is very aware of the rarely discussed, but often disabling, cognitive deficits and emotional symptoms that accompany Cushing’s disease. In this review, we discuss the neurobiological basis of these impairments.

We previously documented a striking radiographic feature of pathological hypercortisolism, namely the marked cortical and subcortical brain atrophy seen in patients with Cushing’s disease (Fig. 1). Brain atrophy, especially in the hippocampus, has been well documented in both adult and pediatric patients treated with exogenous glucocorticoid therapy. In this review, the timing, pathology, and pathophysiology of the brain atrophy in Cushing’s disease are discussed. The correlation of atrophy with cognitive deficits and its reversibility is also reviewed. (DOI: 10.3171/FOC-07/09/E11)

KEY WORDS • brain atrophy • Cushing’s disease • cognitive impairment • glucocorticoids • hippocampal atrophy

Effects of Glucocorticoids on Hippocampal and Brain Volume

Animal Models

Rodent and primate animal models have been developed to investigate the effects of glucocorticoids on the hippocampus. Rodent studies have consistently demonstrated that raising levels of corticosterone, the primary glucocorticoid in rodents, results in a decrease in hippocampal volume. Sapolsky and colleagues stereotactically implanted glucocorticoid and control (cholesterol) pellets in vervet monkeys’ hippocampi and demonstrated hippocampal damage and volume loss after 1 year at postmortem examination. Exposure to excess glucocorticoids does not kill or reduce the number of pyramidal or glial cells in the hippocampus. Several early studies showed cell layer irregularities, soma shrinkage, and condensation of the pyramidal cells after excess glucocorticoid administration. Recent studies that involved rigorous quantitative methods, however, have not shown decreases in pyramidal cell diameter, condensation, or cell layer irregularities.

What, then, accounts for the well-documented decreases in hippocampal volume? On a cellular level, exposure to excess glucocorticoids appears to alter the dendritic shape of the hippocampal pyramidal neurons. The apical dendrites in the CA3 region of the hippocampus decrease in length and show decreased branching. This decrease in apical dendritic neuropil volume (dendritic atrophy) appears to be responsible for the hippocampal volume loss. Decreases in mitochondrial volume have also been reported and may also contribute to hippocampal volume loss. Tata and associates have demonstrated a profound loss of synapses in the CA3 region of the hippocampus, independent of the volume loss. This finding suggests that volume measures may significantly underestimate the effects of glucocorticoids on the brain.

Glucocorticoid receptors are widely distributed throughout the brain. The highest density of glucocorticoid receptors in the central nervous system is in the hippocampus. Coburn-Litvak and colleagues have demonstrated that chronic glucocorticoid exposure not only decreases hip-
The largest decline in cognitive function in this study was found in measures of the verbal intelligence quotient and verbal learning and recall. These impairments are consistent with the clinical cognitive complaints reported by patients with Cushing’s disease. In contrast to dementia, delirium, and aging, which show increased vulnerability across visuospatial measures, verbal functions are most prominently affected in Cushing’s disease. The deficits in verbal intellectual skills suggest involvement of the neocortex, whereas the impairments in verbal learning and recall are consistent with the increasingly accepted view that the hippocampus is especially vulnerable to the effects of glucocorticoids.

Mood disorders, especially depression, are common in patients with Cushing’s disease. Other psychiatric disturbances linked with excess glucocorticoids include anxiety, excitability, hypomania, and psychosis. Although atrophy of the prefrontal cortex has been linked with depression, anxiety and excitability have been correlated with increases in the size and activity of the amygdala. Therefore, the role of glucocorticoids in mediating the mood disturbances noted in patients with Cushing’s disease needs to be elucidated further.

Mechanisms of Glucocorticoid-Induced Brain Atrophy and Hippocampal Changes

Glucocorticoids impair the ability of hippocampal neurons to survive various neurological insults, including hypoxia, ischemia, seizures, and exposure to antimetabolites. Mechanisms by which glucocorticoids induce morphological changes in the brain are largely unknown, although four theories (backed by limited evidence) have been suggested. These four theories are briefly summarized.

Decreased Glucose Utilization

Glucocorticoids decrease glucose uptake in the brain, and over time this may lead to brain atrophy. Glucocorticoids are known to affect cellular glucose metabolism and decrease glucose utilization in peripheral tissues and the brain. As reported by Brunetti and associates, the fluorodeoxyglucose positron emission tomography findings of a generalized reduction in cerebral glucose metabolism in all areas of the brain in patients with Cushing’s disease support the reduced glucose utilization hypothesis.

Increased Actions of EAA Neurotransmitters

Excitatory amino acids such as glutamate are known to cause cell damage. There is some evidence to suggest that glucocorticoids may increase the release or enhance the effects of EAAs. Phenytin, which may decrease the effects of EAAs, prevents the dendritic atrophy produced by excess glucocorticoids in the hippocampus. These findings support the role of glucocorticoid-induced EAAs in the origins of hippocampal and brain atrophy.

Inhibition of LTP and Decrease in Neurotrophic Factors

Long-term potentiation is believed to be the mechanism behind learning and formation of memories. Zhou and coworkers showed that excess glucocorticoids inhibit...
Brain atrophy and cognitive deficits in Cushing’s disease

LTP in rats. In addition, this study demonstrated that glucocorticoids reduce the synthesis of neurotrophic factors such as nerve growth factor-β and brain-derived neurotrophic factor. The reduction of neurotrophic factors may be a presynaptic mechanism by which LTP is inhibited by glucocorticoids. In this theory, brain atrophy is explained by the reduction in neurotrophic factors, and the cognitive deficits are accounted for by the inhibition of LTP.

Decreased Neurogenesis

The subgranular layer of the dentate gyrus is involved in neurogenesis and gives rise to granular neurons.12 There is some evidence that stress and hormonal changes, such as excess glucocorticoids, may suppress neurogenesis in the dentate gyrus. This impaired neurogenesis could account for some of the hippocampal volume loss associated with glucocorticoids.

Duration of Excess Glucocorticoid Exposure and Onset of Cognitive Deficits and Brain Atrophy

Primate studies using exogenous glucocorticoids show that hippocampal changes are present within 1 year of glucocorticoid exposure. Because of the often insidious onset of symptoms in Cushing’s disease, no specific data on exposure duration and brain atrophy are available. Clinical investigations of exogenous glucocorticoid therapy show an exposure duration of as short as 2 to 6 months before changes in the brain and hippocampus are detected.5,21 Cerebral cortical atrophy has been reported within 6 months of glucocorticoid exposure, even in children.21

Several studies have shown an almost immediate decrease in cognitive function when glucocorticoid levels increase to the levels that are seen in animal models of stress. For example, Newcomer and colleagues15 found deficits in verbal declarative memory after 4 days of cortisol exposure. These findings not only emphasize the robust and widespread effects of glucocorticoids on the brain, but also suggest a rapid timeline for brain atrophy and hippocampal reorganization.

Reversibility of Cerebral Atrophy in Cushing’s Disease

Cerebral atrophy has been shown to be reversible in patients with Cushing’s disease.9 Following resection of adrenocorticotropic hormone-secreting pituitary adenomas, hippocampal formation volume has been shown to increase by as much as 10%.23 The increase in hippocampal formation volume correlates with the magnitude of decrease in urinary free cortisol. In addition, improvements in memory correlate with decreases in cortisol levels as well as with increases in hippocampal formation volume.9 Age has been identified as a significant factor that influences the speed of recovery. Younger patients regain and sustain their improvement in cognitive functioning more quickly than older subjects. These findings suggest that at least some of the deleterious effects of prolonged hypercortisolism on cognitive functioning and hippocampal volume are reversible.

In summary, Cushing’s disease is associated with hippocampal and generalized brain atrophy. Excess glucocorticoids cause retraction and simplification of dendrites in the hippocampus, and these morphological changes probably account for the hippocampal volume loss. Furthermore, a profound loss of synapses is also seen in Cushing’s disease. These findings suggest the possibility that volume measures may be underestimating the change in neural structures. Several mechanisms by which glucocorticoids affect the brain include decreased neurogenesis, glucose utilization, and synthesis of neurotrophic factors as well as increased actions of EAA. We have reviewed the evidence correlating hippocampal atrophy and cognitive deficits and have shown that these effects appear to reversible. Further investigations into the mechanisms by which glucocorticoids affect the brain and peripheral tissues are essential. These mechanistic details may eventually provide targets for preventing or treating the brain atrophy, cognitive impairments, and mood disorders common in patients with Cushing’s disease.

References


